Literature DB >> 28759002

SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling.

Victor S Cortez1, Tyler K Ulland1, Luisa Cervantes-Barragan1, Jennifer K Bando1, Michelle L Robinette1, Qianli Wang1, Andrew J White2, Susan Gilfillan1, Marina Cella1, Marco Colonna1.   

Abstract

Among the features that distinguish type 1 innate lymphoid cells (ILC1s) from natural killer (NK) cells is a gene signature indicative of 'imprinting' by cytokines of the TGF-β family. We studied mice in which ILC1s and NK cells lacked SMAD4, a signal transducer that facilitates the canonical signaling pathway common to all cytokines of the TGF-β family. While SMAD4 deficiency did not affect ILC1 differentiation, NK cells unexpectedly acquired an ILC1-like gene signature and were unable to control tumor metastasis or viral infection. Mechanistically, SMAD4 restrained non-canonical TGF-β signaling mediated by the cytokine receptor TGFβR1 in NK cells. NK cells from a SMAD4-deficient person affected by polyposis were also hyper-responsive to TGF-β. These results identify SMAD4 as a previously unknown regulator that restricts non-canonical TGF-β signaling in NK cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28759002      PMCID: PMC5712491          DOI: 10.1038/ni.3809

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  44 in total

1.  Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway.

Authors:  Wei He; David C Dorn; Hediye Erdjument-Bromage; Paul Tempst; Malcolm A S Moore; Joan Massagué
Journal:  Cell       Date:  2006-06-02       Impact factor: 41.582

Review 2.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 3.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

4.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Authors:  Joe-Marc Chauvin; Ornella Pagliano; Julien Fourcade; Zhaojun Sun; Hong Wang; Cindy Sander; John M Kirkwood; Tseng-hui Timothy Chen; Mark Maurer; Alan J Korman; Hassane M Zarour
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

5.  Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells.

Authors:  Anja Fuchs; William Vermi; Jacob S Lee; Silvia Lonardi; Susan Gilfillan; Rodney D Newberry; Marina Cella; Marco Colonna
Journal:  Immunity       Date:  2013-02-28       Impact factor: 31.745

6.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.

Authors:  Sébastien Viel; Antoine Marçais; Fernando Souza-Fonseca Guimaraes; Roisin Loftus; Jessica Rabilloud; Morgan Grau; Sophie Degouve; Sophia Djebali; Amélien Sanlaville; Emily Charrier; Jacques Bienvenu; Julien C Marie; Christophe Caux; Jacqueline Marvel; Liam Town; Nicholas D Huntington; Laurent Bartholin; David Finlay; Mark J Smyth; Thierry Walzer
Journal:  Sci Signal       Date:  2016-02-16       Impact factor: 8.192

7.  A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC.

Authors:  Kent S Boles; William Vermi; Fabio Facchetti; Anja Fuchs; Timothy J Wilson; Thomas G Diacovo; Marina Cella; Marco Colonna
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

8.  A committed precursor to innate lymphoid cells.

Authors:  Michael G Constantinides; Benjamin D McDonald; Philip A Verhoef; Albert Bendelac
Journal:  Nature       Date:  2014-02-09       Impact factor: 49.962

9.  TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy.

Authors:  Jeffrey P Marcoe; James R Lim; Keri L Schaubert; Nassima Fodil-Cornu; Marsel Matka; Alexandra L McCubbrey; Alexander R Farr; Silvia M Vidal; Yasmina Laouar
Journal:  Nat Immunol       Date:  2012-08-05       Impact factor: 25.606

10.  Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection.

Authors:  Mary J van Helden; Steven Goossens; Cécile Daussy; Anne-Laure Mathieu; Fabrice Faure; Antoine Marçais; Niels Vandamme; Natalie Farla; Katia Mayol; Sébastien Viel; Sophie Degouve; Emilie Debien; Eve Seuntjens; Andrea Conidi; Julie Chaix; Philippe Mangeot; Simon de Bernard; Laurent Buffat; Jody J Haigh; Danny Huylebroeck; Bart N Lambrecht; Geert Berx; Thierry Walzer
Journal:  J Exp Med       Date:  2015-10-26       Impact factor: 14.307

View more
  117 in total

Review 1.  Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.

Authors:  Briana G Nixon; Ming O Li
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Transcriptional regulation of murine natural killer cell development, differentiation and maturation.

Authors:  Werner Held; Beena Jeevan-Raj; Mélanie Charmoy
Journal:  Cell Mol Life Sci       Date:  2018-06-29       Impact factor: 9.261

3.  aFARP-ChIP-seq, a convenient and reliable method for genome profiling in as few as 100 cells with a capability for multiplexing ChIP-seq.

Authors:  Wenbin Liu; Sibiao Yue; Xiaobin Zheng; Minjie Hu; Jia Cao; Yixian Zheng
Journal:  Epigenetics       Date:  2019-06-06       Impact factor: 4.528

Review 4.  Innate lymphocytes-lineage, localization and timing of differentiation.

Authors:  Emily R Kansler; Ming O Li
Journal:  Cell Mol Immunol       Date:  2019-02-25       Impact factor: 11.530

Review 5.  Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity.

Authors:  Marco Colonna
Journal:  Immunity       Date:  2018-06-19       Impact factor: 31.745

6.  Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Authors:  Yulong Gao; Fernando Souza-Fonseca-Guimaraes; Tobias Bald; Susanna S Ng; Arabella Young; Shin Foong Ngiow; Jai Rautela; Jasmin Straube; Nic Waddell; Stephen J Blake; Juming Yan; Laurent Bartholin; Jason S Lee; Eric Vivier; Kazuyoshi Takeda; Meriem Messaoudene; Laurence Zitvogel; Michele W L Teng; Gabrielle T Belz; Christian R Engwerda; Nicholas D Huntington; Kyohei Nakamura; Michael Hölzel; Mark J Smyth
Journal:  Nat Immunol       Date:  2017-07-31       Impact factor: 25.606

Review 7.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

Review 8.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

9.  NK cells join the plasticity party.

Authors:  Jonathan S Silver; Alison A Humbles
Journal:  Nat Immunol       Date:  2017-08-22       Impact factor: 25.606

Review 10.  Plasticity of innate lymphoid cell subsets.

Authors:  Suzanne M Bal; Korneliusz Golebski; Hergen Spits
Journal:  Nat Rev Immunol       Date:  2020-02-27       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.